[{"orgOrder":0,"company":"WraSer Pharmaceuticals","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Levoamlodipine","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"WraSer Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"WraSer Pharmaceuticals \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"WraSer Pharmaceuticals \/ Blue Water Vaccines"}]

Find Clinical Drug Pipeline Developments & Deals for Levoamlodipine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Blue Water expands its commercial portfolio by purchasing six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. The assets also include Conjupri (levamlodipine), a calcium channel blocker for the...

                          Product Name : Conjupri

                          Product Type : Other Small Molecule

                          Upfront Cash : $8.5 million

                          June 14, 2023

                          Lead Product(s) : Levoamlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Blue Water Vaccines

                          Deal Size : $8.5 million

                          Deal Type : Acquisition

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 05, 2018

                          Lead Product(s) : Levoamlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Seoul National University Bundang Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Seoul National University Bundang Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 21, 2017

                          Lead Product(s) : Levoamlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Hanlim Pharmaceuticals Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Neutec Ar-Ge San ve Tic A.?

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Neutec Ar-Ge San ve Tic A.?

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 31, 2017

                          Lead Product(s) : Levoamlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 19, 2011

                          Lead Product(s) : Levoamlodipine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Asan Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 27, 2010

                          Lead Product(s) : Levoamlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 21, 2010

                          Lead Product(s) : Levoamlodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank